Membrane plasmalogen composition and cellular cholesterol regulation: A structure activity study

Lipids in Health and Disease

Volumn 9, Issue , 2010, Pages

  Mankidy, Rishikesh ^a   Ahiahonu, Pearson Wk ^a   Ma, Hong ^a   Jayasinghe, Dushmanthi ^a   Ritchie, Shawn A ^a   Khan, Mohamed A ^a   Su Myat, Khine K ^a   Wood, Paul L ^a   Goodenowe, Dayan B ^a  

^a Phenomenome Discoveries Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE 1; CIS 2 O ALPHA LINOLENOYL 1 O HEXADECYLGLYCEROL; CIS 2 O ARACHIDONOYL 1 O HEXADECYLGLYCEROL; CIS 2 O DOCOSAHEXAENOYL 1 HEXADECYLGYCEROL; CIS 2 O DOCOSAHEXAENOYL 1 O HEXADECYLGLYCEROL; CIS 2 O DOCOSAHEXAENOYL 1 O OCTADEC 9 ENYLGLYCEROL; CIS 2 O DOCOSAHEXAENOYL 1 O OCTADECYLGLYCEROL; CIS 2 O DOCOSAHEXAENOYL 1 O PALMITOYLGLYCEROL; CIS 2 O DOCOSAHEXAENOYL 1 O STEAROYLGLYCEROL; CIS 2 O DOCOSAHEXAENOYL 1 OCTODECYLGYCEROL; CIS 2 O LINOLEOYL 1 O HEXADECYLGLYCEROL; CIS 2 O OLEOYL 1 O HEXADECYLGLYCEROL; CIS 2 O STEAROYL 1 O HEXADECYLGLYCEROL; ETHANOLAMINE DERIVATIVE; GLYCEROL DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; PLASMALOGEN; POLYUNSATURATED FATTY ACID; UNCLASSIFIED DRUG; GLYCEROL; PHOSPHATIDAL ETHANOLAMINES; STEROL O ACYLTRANSFERASE 1; STEROL O-ACYLTRANSFERASE 1; UNSATURATED FATTY ACID;

AGING; ARTICLE; CELL MEMBRANE; CELL STRAIN HEK293; CHOLESTEROL ESTERIFICATION; CONTROLLED STUDY; DRUG SYNTHESIS; EMBRYO; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; CELL LINE; CHEMISTRY; ESTERIFICATION; METABOLISM; SPECIES DIFFERENCE;

CELL LINE; CELL MEMBRANE; CHOLESTEROL; ESTERIFICATION; FATTY ACIDS, UNSATURATED; GLYCEROL; HUMANS; PLASMALOGENS; SPECIES SPECIFICITY; STEROL O-ACYLTRANSFERASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953341011     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-62     Document Type: Article

References (66)

1. Membrane cholesterol and the regulation of signal transduction. CJ Fielding PE Fielding, Biochemical Society transactions 2004 32 Pt 1 65 69 10.1042/BST0320065 14748714
2. Effects of cholesterol and oxysterols on gap junctional communication between human smooth muscle cells. RM Zwijsen IM Oudenhoven LH de Haan, European journal of pharmacology 1992 228 2-3 115 120 1446717
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001 285 19 2486 2497 10.1001/jama.285.19.2486 11368702
4. Management of lipid disorders for stroke prevention. SB Fowler M Kelly D Ruh D Johnson-Wells, J Neurosci Nurs 2006 38 4 Suppl 282 287 295 10.1097/01376517-200609000-00003 16989296
5. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. EH Corder AM Saunders WJ Strittmatter DE Schmechel PC Gaskell GW Small AD Roses JL Haines MA Pericak-Vance, Science (New York, NY) 1993 261 5123 921 923
6. The role of cholesterol in prostate cancer. MH Hager KR Solomon MR Freeman, Current opinion in clinical nutrition and metabolic care 2006 9 4 379 385 10.1097/01.mco.0000232896.66791.62 16778565
7. Cholesterol metabolism in the brain. JM Dietschy SD Turley, Current opinion in lipidology 2001 12 2 105 112 10.1097/00041433-200104000-00003 11264981
8. Parameters related to lipid metabolism as markers of myelination in mouse brain. ED Muse H Jurevics AD Toews GK Matsushima P Morell, J Neurochem 2001 76 1 77 86 10.1046/j.1471-4159.2001.00015.x 11145980
9. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. IJ Martins T Berger MJ Sharman G Verdile SJ Fuller RN Martins, J Neurochem 2009 111 6 1275 1308 10.1111/j.1471-4159.2009.06408.x 20050287
10. Adult rat brain synaptic vesicles. II. Lipid composition. WC Breckenridge IG Morgan JP Zanetta G Vincendon, Biochimica et biophysica acta 1973 320 3 681 686 4356538
11. Stabilization of non-bilayer structures by the etherlipid ethanolamine plasmalogen. K Lohner P Balgavy A Hermetter F Paltauf P Laggner, Biochimica et biophysica acta 1991 1061 2 132 140 10.1016/0005-2736(91)90277-F 1998688
12. Rapid plasmenylethanolamine-selective fusion of membrane bilayers catalyzed by an isoform of glyceraldehyde-3-phosphate dehydrogenase: discrimination between glycolytic and fusogenic roles of individual isoforms. PE Glaser RW Gross, Biochemistry 1995 34 38 12193 12203 10.1021/bi00038a013 7547960
13. Unsaturated aminophospholipids are preferentially retained by the fast skeletal muscle CaATPase during detergent solubilization. Evidence for a specific association between aminophospholipids and the calcium pump protein. RJ Bick KA Youker HJ Pownall WB Van Winkle ML Entman, Archives of biochemistry and biophysics 1991 286 2 346 352 10.1016/0003-9861(91)90050-S 1832833
14. Accelerated maximal velocity of the red blood cell Na+/K+ pump in hyperlipidemia is related to increase in 1-palmitoyl,2-arachidonoyl-plasmalogen phosphatidylethanolamine. J Duhm B Engelmann UM Schonthier S Streich, Biochimica et biophysica acta 1993 1149 1 185 188 10.1016/0005-2736(93)90040-7 8391317
15. Plasmalogen and anionic phospholipid dependence of the cardiac sarcolemmal sodium-calcium exchanger. DA Ford CC Hale, FEBS letters 1996 394 1 99 102 10.1016/0014-5793(96)00930-1 8925938
16. Presence of 1-O-alk-1'-enyl-2-O-acetyl glycerophosphocholine (vinyl form of PAF) in perfused rat and guinea pig hearts. R Nakayama K Saito, Journal of biochemistry 1989 105 4 494 496 2760010
17. Platelet-activating factor: receptors and signal transduction. W Chao MS Olson, The Biochemical journal 1993 292 Pt 3 617 629 8391253
18. Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins. B Engelmann C Brautigam J Thiery, Biochemical and biophysical research communications 1994 204 3 1235 1242 10.1006/bbrc.1994.2595 7980601
19. The biological significance of plasmalogens in defense against oxidative damage. T Brosche D Platt, Experimental gerontology 1998 33 5 363 369 10.1016/S0531-5565(98)00014-X 9762517
20. Evidence that plasmalogen is protective against oxidative stress in the rat brain. B Kuczynski NV Reo, Neurochemical research 2006 31 5 639 656 10.1007/s11064-006-9061-7 16770735
21. Increasing plasmalogen levels protects human endothelial cells during hypoxia. RA Zoeller TJ Grazia P LaCamera J Park DP Gaposchkin HW Farber, American journal of physiology 2002 283 2 671 679 12124215
22. Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens. AA Farooqui SI Rapoport LA Horrocks, Neurochemical research 1997 22 4 523 527 10.1023/A:1027380331807 9130265
23. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. Z Guan Y Wang NJ Cairns PL Lantos G Dallner PJ Sindelar, Journal of neuropathology and experimental neurology 1999 58 7 740 747 10.1097/00005072-199907000-00008 10411344
24. Severe plasmalogen deficiency in tissues of infants without peroxisomes (Zellweger syndrome). HS Heymans RB Schutgens R Tan H van den Bosch P Borst, Nature 1983 306 5938 69 70 10.1038/306069a0 6633659
25. Phospholipid composition and levels are altered in Down syndrome brain. EJ Murphy MB Schapiro SI Rapoport HU Shetty, Brain research 2000 867 1-2 9 18 10.1016/S0006-8993(00)02205-8 10837793
26. Peroxisomal impairment in Niemann-Pick type C disease. S Schedin PJ Sindelar P Pentchev U Brunk G Dallner, The Journal of biological chemistry 1997 272 10 6245 6251 10.1074/jbc.272.10.6245 9045641 (Pubitemid 27118096)
27. Ether lipid synthesis and its deficiency in peroxisomal disorders. H van den Bosch G Schrakamp D Hardeman AW Zomer RJ Wanders RB Schutgens, Biochimie 1993 75 3-4 183 189 10.1016/0300-9084(93)90076-5 8507680
28. Neural membrane phospholipids in Alzheimer disease. K Wells AA Farooqui L Liss LA Horrocks, Neurochemical research 1995 20 11 1329 1333 10.1007/BF00992508 8786819
29. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. L Ginsberg S Rafique JH Xuereb SI Rapoport NL Gershfeld, Brain research 1995 698 1-2 223 226 10.1016/0006-8993(95)00931-F 8581486
30. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. X Han DM Holtzman DW McKeel Jr, J Neurochem 2001 77 4 1168 1180 10.1046/j.1471-4159.2001.00332.x 11359882
31. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. DB Goodenowe LL Cook J Liu Y Lu DA Jayasinghe PW Ahiahonu D Heath Y Yamazaki J Flax KF Krenitsky,, et al. Journal of lipid research 2007 48 11 2485 2498 10.1194/jlr.P700023-JLR200 17664527
32. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. P Stenvinkel U Diczfalusy B Lindholm O Heimburger, Nephrol Dial Transplant 2004 19 4 972 976 10.1093/ndt/gfh035 15031358
33. Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging. DB Goodenowe, 2008 In., G01N 33/483 (2006.01) edn. US PCT/CA2008/000659
34. The Molecular Basis of NeuroPathology. LA Horrocks M VanRollins AJ Yates, London 1981
35. Plasmalogens in human serum positively correlate with high- density lipoprotein and decrease with aging. R Maeba T Maeda M Kinoshita K Takao H Takenaka J Kusano N Yoshimura Y Takeoka D Yasuda T Okazaki,, et al. Journal of atherosclerosis and thrombosis 2007 14 1 12 18 17332687
36. Curvilinear regression course of human brain lipid composition changes with age. G Rouser A Yamamoto, Lipids 1968 3 3 284 287 10.1007/BF02531202 17805871
37. Changes of membrane phospholipid composition of human erythrocytes in hyperlipidemias. I. Increased phosphatidylcholine and reduced sphingomyelin in patients with elevated levels of triacylglycerol-rich lipoproteins. B Engelmann S Streich UM Schonthier WO Richter J Duhm, Biochimica et biophysica acta 1992 1165 1 32 37 1420345
38. Plasmalogen phospholipids are involved in HDL-mediated cholesterol efflux: insights from investigations with plasmalogen-deficient cells. H Mandel R Sharf M Berant RJ Wanders P Vreken M Aviram, Biochemical and biophysical research communications 1998 250 2 369 373 10.1006/bbrc.1998.9321 9753636
39. Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. NJ Munn E Arnio D Liu RA Zoeller L Liscum, Journal of lipid research 2003 44 1 182 192 10.1194/jlr.M200363-JLR200 12518037
40. Stereospecific Synthesis of Ether and Thioether Phospholipids. The Use of L-Glyceric Acid as a Chiral Phospholipid Precursor. SK Bhatia J Hajdu, J Org Chem 1988 53 5034 5039 10.1021/jo00256a024
41. Phospholipase-A2-mediated stereoselective synthesis of (R)-1-O-alkylglycero-3-phosphate and alkyl-acyl analogues: application for synthesis of radiolabelled biosynthetic precursors of cell surface glycoconjugates of Leishmania donovani. P Sahai RA Vishwakarma, J Chem Soc, Perkin Trans 1997 1 1845 1849 10.1039/a700353f
42. Lipase-catalyzed kinetic resolution of 1-O-alkylglycerols by sequential transesterification. A Halldorsson P Thordarson B Kristinsson C Magnusson GG Haraldsson, Tetrahedron Asymmerty 2004 15 2893 2899 10.1016/j.tetasy.2004.07.046 (Pubitemid 39278025)
43. Glucosamine-glycerophospholipids that activate cell-matrix adhesion and migration. T Bartolmas T Heyn M Mickeleit A Fischer W Reutter K Danker, Journal of medicinal chemistry 2005 48 21 6750 6755 10.1021/jm050558n 16220990
44. Sensitive method for the analysis of phospholipid subclasses and molecular species as 1-anthroyl derivatives of their diglycerides. CS Ramesha WC Pickett DV Murthy, Journal of chromatography 1989 491 1 37 48 2793981
45. The chemical synthesis of bioactive glycosylphosphatidylinositols from Trypanosoma cruzi containing an unsaturated fatty acid in the lipid. DV Yashunsky VS Borodkin MA Ferguson AV Nikolaev, Angewandte Chemie (International ed) 2006 45 3 468 474 10.1002/anie.200502779 (Pubitemid 43075843)
46. An animal cell mutant with a deficiency in acyl/alkyl-dihydroxyacetone- phosphate reductase activity. Effects on the biosynthesis of ether-linked and diacyl glycerolipids. PF James AC Lake AK Hajra LK Larkins M Robinson FG Buchanan RA Zoeller, The Journal of biological chemistry 1997 272 38 23540 23546 10.1074/jbc.272.38.23540 9295290
47. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. OP Flint BA Masters RE Gregg SK Durham, Toxicology and applied pharmacology 1997 145 1 99 110 10.1006/taap.1997.8174 9221829
48. HMG-CoA reductase and PPARalpha are involved in clofibrate-induced apoptosis in human keratinocytes. G Muzio G Martinasso A Trombetta D Di Simone RA Canuto M Maggiora, Apoptosis 2006 11 2 265 275 10.1007/s10495-006-3559-y 16502264
49. Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line. YC Yang TC Ho SL Chen HY Lai JY Wu YP Tsao, BMC cancer 2007 7 216 10.1186/1471-2407-7-216 18021457
50. Role of dihydroxyacetonephosphate acyltransferase in the biosynthesis of plasmalogens and nonether glycerolipids. D Liu N Nagan WW Just C Rodemer TP Thai RA Zoeller, Journal of lipid research 2005 46 4 727 735 10.1194/jlr.M400364- JLR200 15687349
51. Isolation of a Chinese hamster fibroblast variant defective in dihydroxyacetonephosphate acyltransferase activity and plasmalogen biosynthesis: use of a novel two-step selection protocol. N Nagan AK Hajra LK Larkins P Lazarow PE Purdue WB Rizzo RA Zoeller, The Biochemical journal 1998 332 Pt 1 273 279 9576878 (Pubitemid 28239345)
52. Uber einen weiterbreiteten fasten Aldehyd. R Feulgen K Voit, Arch Physiol 1924 206 217 245
53. [Information on acetalphosphatides.]. E Klenk H Debuch, Hoppe-Seyler's Zeitschrift fur physiologische Chemie 1954 296 3-4 179 188 13221241
54. The structure of plasmalogens. III. The nature and significance of the aldehydogenic linkage. MM Rapport RE Franzl, J Neurochem 1957 1 4 303 310 10.1111/j.1471-4159.1957.tb12086.x 13476195
55. Rapid isolation of neuroblastoma plasma membranes on Percoll gradients. Characterization and lipid composition. BR Chakravarthy MW Spence JT Clarke HW Cook, Biochimica et biophysica acta 1985 812 1 223 233 10.1016/0005-2736(85) 90542-5 3967013
56. Studies on the submicrosomal fractions of bovine oligodendroglia: lipid composition and glycolipid biosynthesis. DS Deshmukh AW Vorbrodt PK Lee WD Bear S Kuizon, Neurochemical research 1988 13 6 571 582 10.1007/BF00973300 3405384
57. Role of the plasma membrane in cholesterol esterification in rat hepatoma cells. Y Lange F Strebel TL Steck, The Journal of biological chemistry 1993 268 19 13838 13843 8314752
58. Cholesterol metabolism in myelin and other subcellular fractions of rat brain. M Spohn AN Davison, Journal of lipid research 1972 13 5 563 570 5075501
59. Reverse cholesterol transport - a review of the process and its clinical implications. SA Hill MJ McQueen, Clinical biochemistry 1997 30 7 517 525 10.1016/S0009-9120(97)00098-2 9399019
60. Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. GH Rothblat FH Mahlberg WJ Johnson MC Phillips, Journal of lipid research 1992 33 8 1091 1097 1431592
61. High density lipoprotein stimulates sterol translocation between intracellular and plasma membrane pools in human monocyte-derived macrophages. M Aviram EL Bierman JF Oram, Journal of lipid research 1989 30 1 65 76 2918251
62. Acyl coenzyme A:cholesterol acyl transferase in macrophages utilizes a cellular pool of cholesterol oxidase-accessible cholesterol as substrate. I Tabas WJ Rosoff GC Boykow, The Journal of biological chemistry 1988 263 3 1266 1272 3422077
63. Docosahexaenoic acid (DHA) and cardiovascular disease risk factors. BJ Holub, Prostaglandins, leukotrienes, and essential fatty acids 2009 81 2-3 199 204 10.1016/j.plefa.2009.05.016 19545988
64. Effect of ACAT inhibition on the progression of coronary atherosclerosis. SE Nissen EM Tuzcu HB Brewer I Sipahi SJ Nicholls P Ganz P Schoenhagen DD Waters CJ Pepine TD Crowe,, et al. The New England journal of medicine 2006 354 12 1253 1263 10.1056/NEJMoa054699 16554527
65. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. JC Tardif J Gregoire PL L'Allier TJ Anderson O Bertrand F Reeves LM Title F Alfonso E Schampaert A Hassan,, et al. Circulation 2004 110 21 3372 3377 10.1161/01.CIR.0000147777.12010.EF 15533865
66. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. MC Meuwese E de Groot R Duivenvoorden MD Trip L Ose FJ Maritz DC Basart JJ Kastelein R Habib MH Davidson,, et al. Jama 2009 301 11 1131 1139 10.1001/jama.301.11.1131 19293413